UTHR Price Prediction Next Week
Based on the provided data and recent market developments, here's the analysis and price prediction for UTHR for the next trading week:
Technical Analysis
The technical indicators show UTHR is currently in a bearish territory with RSI at 36.95, indicating oversold conditions. The stock is trading above its 200-day SMA of $335.56 but below its 20-day SMA of $362.09. The negative MACD of -3.42 suggests downward momentum.
Key Price Levels
- Fibonacci Support 1: $347.05
- Fibonacci Support 2: $338.03
- Fibonacci Resistance 1: $376.28
- Fibonacci Resistance 2: $385.30
Recent Catalysts A significant FDA approval was announced on February 3, 2025, with UTHR receiving clearance for its UKidney xenotransplantation clinical trial. This represents a major milestone as the first-ever human trial of a xeno-organ, with the first transplant expected around mid-2025.
Institutional Activity Recent insider selling activity shows the President and COO sold 619 shares on January 21, 2025. However, institutional sentiment remains mixed with 293 institutions increasing positions while 274 decreased their holdings in the most recent quarter.
Price Prediction for Next Week Based on technical indicators and recent developments:
- Bearish Scenario (60% probability): Price likely to test first support at $347.05
- Base Case (30% probability): Consolidation between $350-$360
- Bullish Scenario (10% probability): Bounce toward $376.28 resistance
Target Price: Expect UTHR to trade around $345-350 by end of next week
Recommendation: SELL
- Current price shows weakness in momentum
- Multiple insider sales
- Technical indicators suggesting continued downward pressure
- Despite positive FDA news, market sentiment remains cautious
The stock is currently trading at $350.71 in pre-market, showing signs of continued weakness. Traders should consider taking short positions with a stop loss above $362 (20-day SMA).
UTHR Similar Chart Price Prediction
The price of UTHR is predicted to go up 3.22%, based on the high correlation periods with INVA. The similarity of these two price pattern on the periods is 92.27%.
UTHR
INVA
Up: 3.22%Similarity: 92.27%
UTHR Revenue Forecast
UTHR EPS Forecast
UTHR FAQs
What is bull’s view on UTHR?
What is bear's view on UTHR?
What is UTHR revenue forecast for next quarter？
UTHR VS S&P500
Tyvaso received FDA approval in 2021 for the additional indication of PH-ILD and FDA approval in 2022 for Tyvaso DPI, which further expands Tyvaso's patient reach.
Tyvaso is administered through oral inhalation, and its unique drug/device combination patent means generic companies will need to gain FDA approval for both the inhaler and the generic drug, which complicates bringing generics to market.
Patients on Remodulin are typically the sickest and very sensitive to dose changes, so physicians may be hesitant to switch current patients to generics or branded competitors.
UTHR Analyst's Forecast
Ashwani Verma
UBS
Strong Buy
2025-01-08
Price Target
$415 → $475
Upside
+29.57%
UBS raised the firm's price target on United Therapeutics to $475 from $415 and keeps a Buy rating on the shares as part of a broader note on the U.S. Pharmaceuticals and Biotechnology industry. The firm believes BioPharma will find it difficult to outperform against a more uncertain macro backdrop in the short-term, and thinks President-elect Trump will be capable of enacting significant legislative change, and that unpredictability is expected to cast a shadow over the space, the analyst tells investors in a research note. There will be continued uncertainty in the space until there is more clarity on Trump's changes, UBS says.
Matthew Kaplan
Ladenburg Thalmann
Strong Buy
2024-10-31
Price Target
$319 → $344
Downside
-8.01%
Joseph Thome
TD Cowen
Strong Buy
2024-10-21
Price Target
$350 → $400
Upside
+7.93%
